Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
6-Thioguanine Blocks EV71 via BIRC3 Autophagy
2026-08-20
The 2025 BMC Microbiology study identifies 6-thioguanine as an in vitro inhibitor of EV71 replication and links its activity to reduced BIRC3-mediated complete autophagy. Its strong cell-based selectivity supports further antiviral investigation, while the single-cell-model design means that efficacy and dosing cannot yet be extrapolated to patients.
-
MK-8745: Aurora A Inhibitor Workflow Guide
2026-08-19
MK-8745 combines high biochemical potency with a selective Aurora A mechanism for connecting mitotic disruption to apoptosis in cancer models. This guide translates retinoblastoma evidence into practical cell-based, tissue-derived, and xenograft assay workflows, with dosing, controls, and troubleshooting recommendations.
-
C8-HSL and Lung Cancer Progression via PI3K/AKT/ERK
2026-08-19
The reference study identifies the bacterial quorum-sensing molecule C8-HSL as a potential host–microbe factor that enhances lung cancer cell proliferation, migration, and invasion through PI3K/AKT/ERK signaling. Its integrated in vitro and in vivo design connects a microbial communication signal with tumor-associated phenotypes while also highlighting important limitations for clinical translation.
-
ML133 HCl: A Practical Kir2.1 Workflow
2026-08-18
ML133 HCl is a selective potassium channel inhibitor for connecting Kir2.1 activity with membrane physiology, PASMC remodeling, and migration phenotypes. This guide translates published PASMC experiments into practical preparation, dosing, assay-design, and troubleshooting decisions.
-
Linoleic Acid Workflows for Redox and Cell Models
2026-08-18
Build reproducible Linoleic Acid assays for oxidative stress, erythrocyte injury, epithelial migration, and essential-fatty-acid biology. This guide combines fresh-solution handling with a translational framework inspired by fasting and fatty-acid signaling research.
-
EZ Cap EGFP mRNA: A Design-to-Assay Guide
2026-08-17
EZ Cap EGFP mRNA 5-moUTP combines Cap1 capping, 5-methoxyuridine, and a defined poly(A) tail for reproducible reporter expression. This guide explains how to interpret fluorescence as a delivery-and-translation signal and how recent mRNA nanoparticle research informs assay design.
-
Verapamil HCl: Calcium Signaling Workflows
2026-08-17
Verapamil HCl enables controlled perturbation of calcium-dependent signaling in myeloma, arthritis, and bone-remodeling models. This practical guide connects dose-response design, combination studies, and troubleshooting with recent evidence linking verapamil to Txnip-regulated osteoporosis biology.
-
Verapamil, TXNIP, and Osteoporosis: Study Analysis
2026-08-16
The reference study identifies TXNIP as a genetically associated and pharmacologically tractable regulator of osteoporosis, and shows that verapamil reduces ovariectomy-induced bone loss in mice. Its combination of human genotype data, cell-based mechanism studies, and in vivo imaging provides a preclinical framework for drug repurposing while leaving clinical efficacy and dosing unresolved.
-
EZ Cap Cy5 Firefly Luciferase mRNA Workflow
2026-08-15
Use one reporter transcript to connect delivery, intracellular trafficking, and protein expression in the same experiment. EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP) combines Cy5 fluorescence, Firefly luciferase, Cap1 capping, and modified nucleotides for practical optimization of mammalian and mucosal mRNA workflows.
-
Verapamil HCl: From Calcium Blockade to Translation
2026-08-14
Verapamil HCl is best understood not only as an L-type calcium channel blocker, but also as a translational perturbation tool linking calcium flux with Txnip-regulated bone remodeling, myeloma apoptosis, and inflammatory disease biology. This article outlines the mechanistic rationale, evidence boundaries, experimental design priorities, and opportunities for biomarker-guided research.
-
Catharanthus Timebomb Defense Against Herbivores
2026-08-14
The reference study shows how Catharanthus roseus coordinates a compartmentalized terpenoid indole alkaloid defense with cold tolerance through the transcription factor HIVE. Its findings reveal a conditional chemical defense in which herbivory activates toxic alkaloid production, whereas cold redirects metabolic resources toward stress adaptation.
-
ALDOB K87 Lactylation in Pulmonary Hypertension
2026-08-13
Yi et al. identify ALDOB lysine-87 lactylation as a metabolic and mitochondrial regulator in pulmonary hypertension, connecting hypoxia-driven glycolysis with DRP1-dependent mitochondrial fission and pulmonary artery smooth muscle cell remodeling. The study combines lactylomic profiling, cell experiments, rodent models, and causal genetic or pharmacological interventions to define a lactate–ALDOB–DRP1 pathway with potential value for mechanistic research.
-
Phosbind Biotin LC: PVDF Detection Guide
2026-08-13
Phosbind Biotin LC is a phosphate-binding reagent for detecting phosphorylated proteins on PVDF membranes without relying on phospho-specific antibody sequence recognition. It is suited to Western Blot workflows using streptavidin-HRP and chemiluminescence, but not to aqueous-only protocols or long-term storage of working solutions.
-
Brefeldin A: From ER Stress to Translational Insight
2026-08-12
Brefeldin A is more than a vesicle transport inhibitor: it is a mechanistic probe for connecting ER–Golgi trafficking failure with protein quality control, ER stress, and apoptosis. This thought-leadership guide outlines how translational researchers can use BFA to build stronger, better-controlled cancer and cell-biology studies.
-
Batimastat (BB-94) for MMP Assays
2026-08-12
Batimastat (BB-94) is a broad-spectrum hydroxamate MMP inhibitor for connecting extracellular proteolysis with cancer invasion, angiogenesis, and neuromuscular synapse development. This practical guide covers assay setup, localized BDNF-processing workflows, dose selection, controls, and troubleshooting for reproducible mechanism studies.